RUA Life Sciences is a holding company for a group of medical device businesses focused on the exploitation of the world's leading long-term implantable biostable polymer (Elast-EonTM).

20 Jul 2022

RUA Life Sciences - FY Results - Investor Presentation video - 18 July 2022

Bill Brown (Chairman) and Caroline Stretton (Group Managing Director) of RUA Life Sciences presented highlights of the company's FY22 Results. They discussed how the business is proceeding on its FDA regulatory pathway. They also talked about what steps are being put in place to ensure high throughput manufacturing from day one of FDA approval, and the developments in their contract manufacturing business.

The full video (below) has been divided into chapters:
0:00:04 Introduction (Bill Brown)
0:02:08 RUA Life Sciences at a glance (Caroline Stretton)
0:06:27 Financial & Operating Highlights
0:12:18 ESG progress
0:14:26 Elast-Eon / vascular graft development progress
0:24:48 Heart valve / structural heart development progress
0:31:54 Summary
00:34:17 Question & Answer sessions

Return to RUA Life Sciences

Register to be first

Get research on the companies that interest you straight to your inbox

Equity Development is a partner to successful companies looking to enhance their investor relations. Our top-rated analysts produce best in class investment research. Based in London, UK, we help our clients connect with investors via presentations and interviews.

Equity Development Limited 2nd Floor, Park House, 16-18 Finsbury Circus, London, EC2M 7EB

Website design & development by Breckenridge